ALLR — Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 6
- Website: https://www.allarity.com
Latest SEC filings for ALLR
- 10-Q — 2026-05-15
- 3 — 2026-05-11
- 8-K — 2026-05-08
- 8-K — 2026-05-06
- ARS — 2026-04-30
- 8-K — 2026-04-28
- 424B3 — 2026-04-27
- EFFECT — 2026-04-27
- S-3/A — 2026-04-24
- S-3/A — 2026-04-24
Latest ALLR news
- — Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now (Zacks Investment Research)
- — Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now (zacks.com)
- — Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development (globenewswire.com)
- — Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research (GlobeNewswire Inc.)
Educational tool only — not investment advice.